Clinical Study Results
There were other adverse reactions, but these happened in fewer participants.
Most common adverse reactions during Part B
Group 16
Adavosertib and olaparib
(Out of 9 participants)
Decrease in the number of blood-clotting fragments 66.7%
called platelets (6)
Decrease in the number of red blood cells (also called 55.6%
anemia) (5)
22.2%
Decreased appetite
(2)
Decrease in the number of white blood cells called 22.2%
leukocytes (2)
Decrease in the number of white blood cells called 22.2%
neutrophils (2)
22.2%
Vomiting
(2)
22.2%
Diarrhea
(2)
How has this study helped patients and
researchers?
This study helped researchers learn about the safety of adavosertib when taken
with olaparib in participants with solid tumors and SCLC.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with the study drugs are planned.
15